Compare BHRB & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHRB | SPTX |
|---|---|---|
| Founded | 1852 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.8M | 1.1B |
| IPO Year | 2023 | 2026 |
| Metric | BHRB | SPTX |
|---|---|---|
| Price | $74.29 | $20.79 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $71.80 | N/A |
| AVG Volume (30 Days) | ★ 124.6K | 94.6K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 173.76 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.62 | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | $41.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.00 | $17.59 |
| 52 Week High | $74.78 | $22.98 |
| Indicator | BHRB | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.55 | N/A |
| Support Level | $61.32 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.57 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 82.71 | 0.00 |
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.